Doxycycline Based Combination for Improving Clinical Outcomes across Spectrum of Covid-19 infections
The world continues to be amidst an unprecedented health crisis caused by the global spread of a novel coronavirus, SARS-CoV-2 which leads to respiratory, and multi-organ viral infection, termed as COVID-19. The pandemic has so far resulted in 35 million infections and more than one million mortalities 1 . It is noteworthy that almost all patients present initially with a mild- moderate disease; however, about 15% of them progress within 5-14 days post-infection to a more advanced stage of the disease, rendering them critical patients 2 . The highest risk patients seem to be elderly, obese, those suffering from type 2 diabetes, cardiovascular disease, and immunosuppressed.
In a scientific endeavour for clinically utilizing an effective therapy for COVID-19 patients - this recently published clinical trial is aimed to assess if doxycycline based combinational therapy can improve outcomes in treating COVID-19 infections, specifically including patients across the different clinical spectrum of disease. 3
The above article has been published by Medical Dialogues under the MD Brand Connect Initiative. For more details on Doxycycline, click HERE